At Immunovant, I led sponsor-side Veeva Vault CTMS implementation and release planning across seven global IMVT-1402 studies. I coordinated validation and data-flow integration with three CRO partners and the IRT system, and built automated Power BI reporting for leadership.
At Rapport Therapeutics, I managed RAP-219 program planning across a Phase 2a study and indication planning in neuropathic pain and bipolar disorder. I built bipolar IND timelines and a start-up cost scenario that supported the program team’s committee-endorsed recommendation to request a pre-IND meeting and commit $2M in at-risk CRO spending.
At Centessa Pharmaceuticals, I built SerpinPC’s integrated development plan and coordinated its IND package and FDA responses through clearance. The IND was cleared without a clinical hold in September 2022, and I introduced six-week look-ahead timeline reporting that Centessa adopted across three programs.
Earlier, I managed development and governance work at Arcturus Therapeutics and Akebia Therapeutics, including vadadustat post-submission deliverables through Japanese approval. I also built a foundation in biologics manufacturing, quality systems and clinical-development processes, alongside a biology degree and an MBA.
